RDP-58 SangStat Medical

IDrugs

Volumn 6, Issue 12, 2003, Pages 1188-1194

  Holtmann, Martin M ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZATHIOPRINE; BLEOMYCIN; CONCANAVALIN A; CYCLOSPORIN; CYCLOSPORIN A; DEXTRAN SULFATE; DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO ARGINYL DEXTRO NORLEUCYL DEXTRO NORLEUCYL DEXTRO NORLEUCYLGLYCYL DEXTRO TYROSINAMIDE; ETANERCEPT; INFLIXIMAB; IRINOTECAN; LIPOPOLYSACCHARIDE; MESALAZINE; PEPTIDE; PLACEBO; SNAKE VENOM; TENOFOVIR; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; CLINICAL TRIAL; CROHN DISEASE; DIARRHEA; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; ENTERITIS; GASTROINTESTINAL DISEASE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LUNG DISEASE; NAUSEA; NONHUMAN; PERIODONTAL DISEASE; REVIEW; STRUCTURE ACTIVITY RELATION; TOXICITY; TREATMENT INDICATION; ULCERATIVE COLITIS; VOMITING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0347724170     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. 307593 Computer-assisted rational design of immunosuppressive compounds. Grassy G, Calas B, Yasri A, Lahana R, Woo J, Iyer S, Kaczorek M, Floch R, Buelow R Nat Biotechnol 1998 16 8 748-752 Describes the development of RDP-58 using computer screening of virtual combinatorial libraries. An important article for those who are interested in the use of hybridization techniques for optimizing the drug discovery process.
2. 362474 RDP1258, a new rationally designed immunosuppressive peptide, prolongs allograft survival in rats: Analysis of its mechanism of action. Cuturi MC, Christoph F, Woo J, Iyer S, Brouard S, Heslan JM, Pignon P, Soulillou JP, Buelow R Mol Med 1999 5 12 820-832 In vivo study demonstrating that RDP-58 heterotropic heart graft survivalin rats and was correlated with a decrease in TNFα mRNA expression and an incrase in iNOS mRNA levels.
3. 362474 In vitro and in vivo immunomodulatory effects of RDP1258, a novel synthetic peptide. Magee CC, Azuma H, Knoflach A, Denton MD, Chandraker A, Iyer S, Buelow R, Sayegh M J Am Soc Nephrol 1999 10 9 1997-2005 In vivo study demonstrating that RDP-58 prolonged graft survival in a rat renal transplantation model.
4. 362476 Prolongation of heart xenograft survival in a hamster-to-rat model after therapy with a rationally designed immunosuppressive peptide. Brouard S, Cuturi MC, Pignon P, Buelow R, Loth P, Moreau A, Soulillou JP Transplantation 1999 67 12 1614-1618
5. 366839 Oral administration of an immunomodulatory peptide attenuates colitis in mice and non-human primates. Iyer S, Chen Y, Roberts J, Boismenu R, Buelow R Gastroenterology 2000 118 4 Suppl 2 Abs 3026
6. 373741 Inhibition of tumor necrosis factor mRNA translation by a rationally designed immunomodulatory peptide. Iyer S, Kontoyiannis D, Chevrier D, Woo J, Mori N J Biol Chem 2000 275 22 17051-17057 Important work demonstrating the efficacious inhibition of TNFα by RDP-58 in vitro in two model cell lines and in vivo in a mouse model.
7. 383796 SangSat receives NIH grant for the study of RDP-58 in primate model of HIV infection. SangSat Medical Corp Press Release 2000 September 27
8. 398587 Inhibiting TNFα at the translational level - Case Study in RDP58. Buelow R SMI Conf - Cytokines as Drug Targets Ther 2001 January 29-30
9. 398730 Cytokines as Drug Targets, London, UK. Anderson DW IDDB Meeting Report 2001 January 29-30
10. 410760 RDP 1258, a novel immunomodulatory peptide, decreases tumor necrosis factor in Crohn's disease and suppresses inflammation in experimental colitis. Boureille A, Doubremelle M, Raingeard D, De La Bletiere D, Toquet C, Buelow R, Galmiche JP Gastroenterology 2001 120 5 (Suppl 1) 3703
11. 420751 US Specialty Pharmaceuticals: Monthly Dose - May. Merril Lynch Capital Markets 2001 May
12. 423030 US Specialty Pharmaceuticals: Monthly dose. Merril Lynch Capital Markets April
13. 426399 SangStat launches phase II investigation of RDP58 in treatment of Crohn's disease and ulcerative colitis. SangStat Medical Corp Press Release 2001 October 22
14. 447236 RDP58 significantly improves survival and decreases diarrhea related to chemotherapy in animal studies - New SangStat data presented at the American Association for Cancer Research Annual Meeting may lead to improved outcomes for patients with colorectal cancer. SangStat Medical Corp Press Release 2002 April 10 Improvement of chemotherapy tolerability in a mouse model treated with RDP-58.
15. 448349 Novel Targets in Inflammation Research - BIRA's Spring Meeting (PART I), Nottingham, UK. Williams S IDDB Meeting Report 2002 April 11-12
16. 451007 RDP-58, a new oral inhibitor of TNFα effectively treats primate models of colitis and is safe in man. Ganesan S, Iyer S, Travis S, Roberts J, Buelow R, Jazrawi R, Tesi RJ Gastroenterology 2002 122 4 Suppl 1 Abs 45 In vivo study demonstrating abrogation of colitis by RDP-58 in non-human primates and data from a phase I study demonstrating that RDP-58 has no toxic side effects.
17. 451598 The efficacy of RDP58 in the dextran sulfate (DSS) model of chronic colitis. Murthy S, Flanigan A, Buelow R Gastroenterology 2002 122 4 Suppl 1 Abs T1003
18. 451649 Digestive Disease Week 2002 (Part I) - Overnight Report, San Francisco, CA, USA. Veryard C IDDB Meeting Report 2002 May 19-22
19. 451859 Effect of the topical tumor necrosis factor α inhibitor RDP58 on mucosal injury in an experimental model of colitis in rats. Zeeh JM, Schoenfeld DV, Dirsch O, Ji Y, Eysselein VE, Buelow R, Gerken G Gastroenterology 2002 122 4 Suppl 1 Abs T992 In vivo study demonstrating that RDP-58 abrogates experimental TNBS-induced colitis in rats.
20. 451967 RDP58 resolves chronic colitis in primates within 1 day. SangStat Medical Corp Press Release 2002 May 21
21. 459122 Role of cytokines in the pathogenesis of inflammatory bowel disease. Papadakis KA, Targan SR Annu Rev Med 2000 51 289-298
22. 460982 SangStat initiates new RDP58 studies in inflammatory bowel disease. SangStat Medical Corp Press Release 2002 August 12
23. 474482 SangStat receives approval of IND for RDP58 in chemotherapy-induced diarrhea. SangStat Medical Corp Press Release 2002 December 18
24. 476012 SangStat Medical Corporation. Hambrecht & Quist 2003 January 06-09 326-327
25. 476339 SangStat - Presentation at the JPMorgan H&Q 21st Annual Healthcare Conference. Company Presentation 2003 January 06-09
26. 476528 Gastroenterology Week - Tenth United European Annual Meeting (Part III): Falk Symposium Targets of Treatment in Chronic Inflammatory Bowel Diseases, Freiburg, Germany. Schmitz G, Zahn A IDDB Meeting Report 2002 October 06-08
27. 477280 Orally administered RDP58 reduces the severity of dextran sodium sulphate induced colitis. Boismenu R, Chen Y, Chou K, El Sheikh A, Buelow R Ann Rheum Dis 2002 61 Suppl 2ii 19-24 In vivo study demonstrating mechanisms of action of RDP-58 in abrogation of colitis, including downregulation of TNFα expression, reversal of the inhibition of colonic epithelial cell proliferation during DSS treatment and prevention of colonic epithelial cell death and the accumulation of neutrophils in the colon.
28. 477281 RDP58, a locally active TNF inhibitor, is effective in the dextran sulphate mouse model of chronic colitis. Murthy S, Flanigan A, Coppola D, Buelow R Inflamm Res 2002 51 11 522-531
29. 485174 Preliminary results of SangStat's phase II studies of RDP58 show peak response of 77% and a 71% remission rate in patients. SangStat Medical Corp Press Release 2003 April 09 Preliminary respor that RDP-58 induced a statistically significant response rate of 77% in patients with UC at a dose of 200 mg/day, although it was not effective at this dose in CD.
30. 490242 The role of cytokines in the pathogenesis of rheumatoid arthritis. Feldmann M, Maini RN Rheumatology (Oxford) 1999 38 (Suppl 2) 3-7
31. 490499 RDP58, a novel anti-inflammatory peptide, inhibits multiple intracellular messenger pathways and transcription factors to block TNFα, IFNγ, and IL-12 production. Lazarov M, Welihinda A, Muhr E, Mo L, Buelow R, Fong T Gastroenterology 2003 124 Abs 770
32. 490506 New research suggests RDP58 is first drug to reduce inflammation by targeting the 'TRAFYK' protein complex. SangStat Medical Corp Press Release 2003 May 21
33. 491865 New research presented at ASCO shows RDP58 allowed increased dosing of chemotherapy in mice without increased GI toxicities. SangStat Medical Corp Press Release 2003 June 02
34. 491918 Enhanced tumor responses with higher doses of CPT-11 without concomitant gastrointestinal toxicity after oral administration of RDP58 peptide. Zhao J, Huang L, Belmar N, Buelow R, Fong T Proc Am Soc Clin Oncol 2003 22 Abs 855
35. 496634 RDP58, a novel anti-inflammatory peptide, protects mice from chemotherapy-associated gastrointestinal toxicity and mortality. Zhao J, Huang L, Belmer N, Buelow R, Fong T Proc Annu Meet Am Assoc Cancer Res 2003 44 Abs 3740
36. 497898 Inhibition of cutaneous UV light-induced tumor necrosi factor-α protein production of Allotrap 1258, a novel immunomodulatory peptide. Oberyszyn TM Photochem Photobiol 2001 73 2 184-190
37. 498143 RDP58 reduces bladder inflammation in a murine model of acute inflammatory cystitis. Gonzalez RR, Sher K, Fong T, Te A J Urol 2003 169 4 Suppl 68-69
38. 498236 RDP58, an anti-inflammatory peptide, reduces acute and chronic LPS induced pulmonary inflammation. Belmar N, Zhao J, Buelow R, Fong T Inflamm Res 2003 6 S147 Poster 92
39. 498239 RDP58, a rationally designed peptide, inhibits inflammation and bone resorption in a rat model of periodontitis. Lazarov M, Fong TC Inflamm Res 2003 6 S157 Poster 141 Data demonstrating that RDP-58 improves experimentally induced periodontitis.
40. 499313 SangStat reports record revenues of $33.4 million in Q2 2003 and earnings per share of $0.07. SangStat Medical Corp Press Release 2003 July 28
41. 499434 RDP58, a novel immunomodulatory peptide with anti-inflammatory effects. A pharmacological study in trinitrobenzene sulphonic acid colitis and Crohn disease. Bourreille A, Doubremelle M, De La Bletiere DR, Segain JP, Toquet C, Buelow R, Galmiche JP Scand J Gastroenterol 2003 38 5 526-532 Ex vivo study demonstrating that RDP-58 induced inhibition of TNFα and IFNγ in lamina propria mononuclear cells isolated from patients with CD.
42. 500033 Inflammation 2003 - Sixth World Congress (Part I) - Overnight Report, Vancouver, Canada. Evans R IDDB Meeting Report 2003 August 02-06
43. 500323 RDP58, an anti-TNFα peptide, reduce bleomycin-induced pulmonary inflammation and fibrogenesis in mouse lungs. Zhao J, Huang L, Gao L, Beulow R, Fong T Inflamm Res 2003 52 (Suppl 2) Abs 2.10
44. 500525 RDP58, an anti-inflammaory peptide, reduces acute and chronic LPS induced pulmonary inflammation. Belmar N, Zhao J, Buelow R, Fong T Inflamm Res 2003 52 (Suppl 2) Abs 92
45. 500533 RDP58, a rationally designed peptide, inhibits inflammation and bone resorption in a rat model of periodontitis. Lazarov M, Fong T Inflamm Res 2003 52 (Suppl 2) Abs 141
46. 504457 Early regeneration of CD4+CD8+ and naive CD4+ intestinal T-lymphocytes in gut lymphoid tissue of SIV rhesus macaques following combined treatment with PMPA and TNF-α inhibitor RDP58. Reay E, Guadalupe M, Sankaran S, George M, Iyer S, Buelow R, Dandekar S FASEB J 2003 17 7 C298 Data demonstrating that RDP-58 induces a rapid regeneration of intestinal T-cell population after SIV infection of non-human primates.
47. 509320 RDP58, a novel immunomodulatory peptide, ameliorates clinical symptoms in the acute Lewis rat model of experimental autoimmune encephalomyelitis. FASEB J 2003 17 7 C48
48. 509335 RDP58, a rationally designed peptide inhibits multiple forms of pathogenic inflammation through the inhibition of p38MAPK and JNK. Iyer S, Zhao J, Lazarov M, Welihinda A, Buelow R, Gonzalez R, Te A, Fong TC Biopolymers 2003 71 3 400-401